We are live on ! Find out more
BCM

Bridgeway Capital Management Portfolio holdings

AUM $4.97B
1-Year Est. Return 44.96%
This Fund
S&P 500
This Quarter Est. Return
+6.16%
1 Year Est. Return
+44.96%
3 Year Est. Return
+114.45%
5 Year Est. Return
+175.29%
10 Year Est. Return
+704.02%
AUM
$8.76B
AUM Growth
+$460M
Cap. Flow
+$106M
Cap. Flow %
1.21%
Top 10 Hldgs %
10.77%
Holding
1,514
New
104
Increased
381
Reduced
276
Closed
126

Top Sells

Rank Stock Value
1
ANDV
Andeavor
ANDV
+$70.5M
2
T icon
AT&T
T
+$52.8M
3
FCX icon
Freeport-McMoran
FCX
+$47M
4
CME icon
CME Group
CME
+$46.3M
5
MRO
Marathon Oil Corporation
MRO
+$41.4M

Sector Composition

Rank Sector Weight
1 Financials 23.37%
2 Industrials 14.93%
3 Technology 13.85%
4 Consumer Discretionary 11.09%
5 Healthcare 9.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TVRD
951
Tvardi Therapeutics
TVRD
$20.1M
$753K 0.01%
1,528
-694
-31% -$348K
DXYN
952
DELISTED
Dixie Group Inc
DXYN
$753K 0.01%
188,200
+77,600
+70% +$327K
VCRA
953
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$753K 0.01%
24,000
+2,350
+11% +$64.8K
AAIC
954
DELISTED
Arlington Asset Investment Corp.
AAIC
$751K 0.01%
59,000
NAUH
955
DELISTED
National American University Holdings, Inc.
NAUH
$751K 0.01%
350,988
HSTO
956
DELISTED
Histogen Inc. Common Stock
HSTO
$748K 0.01%
682
+19
+3% +$21.6K
PCO
957
DELISTED
Pendrell Corporation - Class A
PCO
$744K 0.01%
1,089
CFMS
958
DELISTED
Conformis, Inc. Common Stock
CFMS
$736K 0.01%
8,368
+2,000
+31% +$198K
CBMG
959
DELISTED
Cellular Biomedicine Group, Inc.
CBMG
$736K 0.01%
69,100
SYNA icon
960
Synaptics
SYNA
$4.05B
$733K 0.01%
+18,700
New +$843K
SPXC icon
961
SPX Corp
SPXC
$9.39B
$731K 0.01%
+24,900
New +$654K
CORT icon
962
Corcept Therapeutics
CORT
$9.98B
$730K 0.01%
37,800
-13,900
-27% -$207K
LEAF
963
DELISTED
Leaf Group Ltd.
LEAF
$730K 0.01%
105,800
-27,905
-21% -$199K
EBS icon
964
Emergent Biosolutions
EBS
$379M
$728K 0.01%
18,000
-1,900
-10% -$68.7K
GNE icon
965
Genie Energy
GNE
$370M
$728K 0.01%
111,167
NVRI icon
966
Enviri
NVRI
$624M
$727K 0.01%
+34,800
New +$594K
UPLD icon
967
Upland Software
UPLD
$13.3M
$725K 0.01%
3,425
-1,800
-34% -$413K
LAB icon
968
Standard BioTools
LAB
$342M
$724K 0.01%
143,572
ITRI icon
969
Itron
ITRI
$4.48B
$723K 0.01%
9,335
-22,665
-71% -$1.64M
DALN
970
DELISTED
DallasNews
DALN
$720K 0.01%
39,151
+7,625
+24% +$151K
IBP icon
971
Installed Building Products
IBP
$6.21B
$719K 0.01%
11,100
-1,200
-10% -$67.3K
ASPS icon
972
Altisource Portfolio Solutions
ASPS
$58.4M
$714K 0.01%
3,450
-375
-10% -$69.8K
DLHC icon
973
DLH Holdings
DLHC
$78.3M
$713K 0.01%
+110,000
New +$651K
NGNE icon
974
Neurogene
NGNE
$672M
$710K 0.01%
2,500
TNK icon
975
Teekay Tankers
TNK
$2.71B
$709K 0.01%
54,689
-22,162
-29% -$284K

Similar funds

Bridgeway Capital Management's Q3 2017 Portfolio in Review

As of Q3 2017, Bridgeway Capital Management held 1,514 positions worth $8.76B, up 5.5% from $8.3B the previous quarter. Its ten largest holdings account for 11% of the portfolio.

Bridgeway Capital Management's Q3 2017 filing shows 104 new, 381 increased, 276 reduced and 126 closed positions. Its largest new stake was Ameren: 832,900 shares worth $48.2M. The largest sale was Andeavor, an estimated $70.5M.

By sector, the portfolio is most concentrated in Financials at 23% of assets, down from 25% a quarter earlier, followed by Industrials and Technology.

  • Bridgeway Capital Management's largest Q3 2017 buy was Ameren: 832,900 shares worth $48.2M.
  • Bridgeway Capital Management added most to Comcast in Q3 2017, an estimated $46.5M increase.
  • Bridgeway Capital Management's biggest Q3 2017 reduction was AT&T, cutting an estimated $52.8M.
  • Bridgeway Capital Management fully exited Andeavor in Q3 2017, selling an estimated $70.5M.
  • Bridgeway Capital Management's ten largest holdings make up 11% of its $8.76B portfolio in Q3 2017.
  • Bridgeway Capital Management opened 104 new positions and closed 126 in Q3 2017.
  • Bridgeway Capital Management's portfolio value rose 5.5% quarter-over-quarter to $8.76B.

Based on Bridgeway Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.